The FDA has recently required the manufacturers of the drug metoclopramide, more commonly know as Reglan, to place a black box warning on its label alerting consumers of the link between the drug and a condition called tardive dyskinesia. Tardive dyskinesia is characterized by involuntary and repetitive movements of the body. A black box warning is the strongest warning that the FDA can require.